May 2010 - Bay Bio Events

May 11, 2010: Medical Device Breakfast Series | How the FDA's 510(k) Programs Are Changing
Medical device start-ups face intense competition for a finite amount of available capital funding. With fears growing among investors that 510(k) clearances are no longer as quick, easy and inexpensive as they used to be, funding for companies hoping to enter the market via 510(k) is drying up. Many of them are no longer seen as a guaranteed low-risk investment. How real are these concerns? How is the FDA's 510(k) program changing? What are the real-life experiences of companies that have recently used the process? A panel of regulatory and business experts will share their up-to-date knowledge, so you can decide for yourself whether your 510(k) strategy is still viable or in need of re-evaluation. In Palo Alto.
Detailed Information

May 12: BayBio Executive Series | Managing the Board
The Board of Directors should be one of the strongest assets a company possesses. It is the one asset that can be both long term and strategic as well as short term and operational. The Board of Directors can function to provide leadership, to be an advisor, to be a sounding board and to even help with implementation in certain circumstances. Within this scope of potential involvement, the board members need to be strategically managed like any other asset. This hard task falls on the CEO, who is charged with maintaining a vibrant and productive board, strategic recruitment, resolving conflicts of interest, aligning visions of the board and executive team, executing effective communications, evaluating board member performance to ensure each director is providing necessary value to the company, and dealing with disruptive or inadequate board members. Attending life sciences CEOs and CFOs will be able to gather and share unique personal insights and recommendations of how to work most effectively with a Board of Directors in both public and private company settings. Open to C Suite Executives of Life Sciences Companies Only. This event is by invitation only and the invitation is not transferrable.
Detailed Information

May 19: California Life Sciences Day
Join leaders in biotechnology, medical devices, pharmaceuticals and biomedical research in Sacramento on Wednesday, May 19, 2010 to build support for the issues that matter most to California's medical innovators. Attendees will participate in face-to-face meetings with legislators and state government officials, enjoy a networking luncheon and join legislators and their staffs at a closing reception. By joining forces and speaking with one voice, we can successfully advocate the collective economic impact and human value of our work. In Sacramento.
Detailed Information

May 25-27: 12th Annual C21 BioVentures
2010 is a year of opportunity for early stage biotech, partners and investors. The best of early-stage biotech have proven their value in 2009. New markets are expanding, new technologies are emerging, and companies are focused on securing partners to build their future. C21 BioVentures puts you at the center of a vibrant, fast-paced network of companies, investors, and partners providing an open, vibrant format for you to connect with the future of biotech in 2010. C21 BioVentures is a critical part of the TVG conference network and attracts a targeted audience of senior executives from the biotechnology, pharmaceutical, and venture capital communities. These groups come to C21 to build relationships and discuss financing opportunities, network, and partner new innovative products and technologies. BayBio life sciences members can take 10% off registration using this code: 10c21baybio10. In Napa, CA.
Detailed Information

May 27, 2010: Therapeutic Breakfast Series | Alternative Partnering and Financing Approaches for Emerging Companies
2009 felt like a tough year for the pharma and biotech industry—especially for many emerging companies. Assets with definitive value stories in “hot” therapeutic areas such as oncology, CNS, and metabolics floated to the top and were able to move their assets forward through the traditional means of partnering and venture capital. A “silver lining” emerged toward the end of last year as the number of phase 2 deals jumped in the second half. For many large pharmaceutical companies and investors, these assets were deemed the most favorable in terms of risk and potential reward given the current market’s dynamics. With that said, many pre-proof of concept assets and late-stage assets set to enter complex or competitive markets were pushed aside. This may be leaving some valuable opportunities for partners willing to license or invest in assets in other areas. Many emerging companies have been “on the road” telling their value story for an extended period of time. For those companies still looking for the deal to move their assets to the next level, what new deal structures are being considered and how can companies can tap into them? During this interactive panel discussion, we will hear success stories as well as from executives who are still in pursuit of their next transaction. In Redwood City.
Detailed Information